AZD2281 (KU-0059436), a PARP (poly ADP-ribose polymerase) inhibitor with single agent anticancer activity in patients with BRCA deficient ovarian cancer: Results from a phase I study

被引：42
|
作者：
Fong, P. C.
Boss, D. S.
Carden, C. P.
Roelvink, M.
De Greve, J.
Gourley, C. M.
Carmichael, J.
De Bono, J. S.
Schellens, J. H.
Kaye, S. B.
机构：
[1] Royal Marsden Hosp, London SW3 6JJ, England
[2] Netherlands Canc Inst, Amsterdam, Netherlands
[3] UZ Brussel, Ctr Oncol, Brussels, Belgium
[4] Univ Edinburgh, Edinburgh, Midlothian, Scotland
[5] Kudos Pharmaceut, Cambridge, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.5510
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5510
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Preliminary results of a phase I trial of ABT-888, a poly(ADP-ribose) polymerase (PARP) inhibitor, in combination with cyclophosphamide.
    Tan, A. R.
    Gibbon, D.
    Stein, M. N.
    Moss, R. A.
    Karantza, V.
    Lin, H.
    Gounder, M.
    Chen, A. P.
    Egorin, M. J.
    DiPaola, R. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [22] Pre-clinical evaluation of single-agent activity of the PARP inhibitor olaparib (AZD2281) in homologous recombination deficient triple-negative breast cancer
    Knights, Charlotte
    Riches, Lucy
    Lau, Alan
    Mangena, Ramu
    Avis, Tim
    Finn, Richard
    O'Shaughnessy, Aisling
    Cranston, Aaron
    Kalous, Ondrej
    Conklin, Dylan
    Carmichael, James
    Slamon, Dennis
    O'Connor, Mark
    CANCER RESEARCH, 2009, 69
  • [23] Phase I pharmacolkinetic (PK) and pharmacodynamic (PD) evaluation of an oral small molecule inhibitor of Poly ADP-Ribose Polymerase (PARP), Ku in patients (p) with advanced tumours
    de Bono, J. S.
    Fong, P. C.
    Boss, D.
    Spicer, J.
    Roelvink, M.
    Tutt, A.
    Mortimer, P.
    O'Connor, M.
    Schellens, J. H. M.
    Kaye, S. B.
    EJC SUPPLEMENTS, 2006, 4 (12): : 153 - 153
  • [24] Adverse events as a potential clinical marker of antitumor efficacy in ovarian cancer patients treated with poly ADP-ribose polymerase (PARP) inhibitor
    Ni, Jing
    Chen, Xiaoxiang
    Xu, Xia
    Guo, Wenwen
    Cheng, Xianzhong
    Zhao, Qian
    Gu, Hongyuan
    Zhou, Rui
    Chen, Chen
    GYNECOLOGIC ONCOLOGY, 2021, 162 : S85 - S86
  • [25] Integrated safety analysis of the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib in patients (pts) with ovarian cancer in the treatment and maintenance settings
    Kristeleit, R. S.
    Oza, A. M.
    Oaknin, A.
    Aghajanian, C.
    Tinker, A. V.
    Tredan, O.
    O'Malley, D. M.
    Leary, A.
    Konecny, G. E.
    Lorusso, D.
    Weberpals, J. I.
    Goble, S.
    Maloney, L.
    Cameron, T.
    Swisher, E.
    McNeish, I. A.
    Shapira-Frommer, R.
    Ledermann, J. A.
    Coleman, R. L.
    ANNALS OF ONCOLOGY, 2019, 30 : 409 - +
  • [26] Poly (ADP-Ribose) Polymerase Inhibitor Olaparib-Resistant BRCA1-Mutant Ovarian Cancer Cells Demonstrate Differential Sensitivity to PARP Inhibitor Rechallenge
    Shih, Chi-Ting
    Huang, Tzu-Ting
    Nair, Jayakumar R.
    Ibanez, Kristen R.
    Lee, Jung-Min
    CELLS, 2024, 13 (22)
  • [27] The use of poly(ADP-ribose) polymerase (PARP1) inhibitors (AG14361, AZD2281, ABT888) in combination with capecitabine, 5-fluorouracil, or paclitaxel in the treatment of hereditary and sporadic breast and ovarian cancer
    De Soto, J. A.
    Quick-Fountain, R.
    Velikodvorskaya, T.
    Fatima, N.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [28] Poly (ADP-ribose) polymerase (PARP) inhibitor regimens for ovarian cancer in phase III randomized controlled trials: a network meta-analysis
    Gong, Han
    Nie, Dan
    Huang, Yue
    Li, Zhengyu
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 (10) : 1576 - 1582
  • [29] First in human trial of a poly(ADP)-ribose polymerase (PARP) inhibitor MK-4827 in advanced cancer patients (p) with antitumor activity in BRCA-deficient and sporadic ovarian cancers
    Wenham, R. M.
    Sandhu, S. K.
    Wilding, G.
    Sun, L.
    Toniatti, C.
    Stroh, M.
    Carpenter, C.
    de-Bono, J.
    Baird, R.
    Schelman, W. R.
    EJC SUPPLEMENTS, 2010, 8 (07): : 114 - 115
  • [30] A Biomarker Study of Poly(ADP-ribose) Polymerase Inhibitor (PARPi) ABT-888 Activity On Ex Vivo Tissue From Ovarian Cancer Patients
    Weberpals, J.
    Ma, X.
    Dimitroulakos, J.
    Djordjevic, B.
    Lapointe-Milot, K.
    Al Mutairi, N.
    Pelletier, L.
    Oza, A.
    Squire, J.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 146 - 146
12345